Caroline Awh
Ophthalmology · Boston, MANPI 1750919569
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.8%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 43.1% of the total. Reporting peaked in 2023 at $2,116 and has fallen 74.7% since, to $535 in 2025.
Across 36 payments — averaging $91.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$1K
- Regeneron$1K
- Alcon$444
- Apellis Pharmaceuticals, Inc.$177
- AbbVie$157
- Dutch Ophthalmic, USA$57
- plus $34 from 2 others
What the payments were for
- Grants$1,00030%
- Travel & lodging$81725%
- Food & beverage$1,47345%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 18 | $1,420 |
| Regeneron | 2 | $1,000 |
| Alcon | 8 | $444 |
| Apellis Pharmaceuticals, Inc. | 3 | $177 |
| AbbVie | 2 | $157 |
| Dutch Ophthalmic, USA | 1 | $57 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS ELITE$906
- Unity$135
- OZURDEX$118
- Hydrus Microstent$116
How this compares
$3,290 in reported general payments places this provider in the 75th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 66 | $2,074 |
| Brimonidine Tartrate | 43 | $1,174 |
| Latanoprost | 71 | $868 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 57 | $647 |
| MoxifloxacinMoxifloxacin Hcl | 22 | $566 |
| Atropine Sulfate | 23 | $506 |
| Ketorolac Tromethamine | 20 | $424 |
| ErythromycinErythromycin Base | 11 | $138 |
| Timolol Maleate | 15 | $99 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.